Britannin inhibits cell proliferation, migration and glycolysis by downregulating KLF5 in lung cancer

Wang,Ying; Yu,Botao; Qu,Mengyuan; Liu,Fengjuan; Wu,Xiao

doi:10.3892/etm.2024.12397

Britannin inhibits cell proliferation, migration and glycolysis by downregulating KLF5 in lung cancer

Authors:
- Ying Wang
- Botao Yu
- Mengyuan Qu
- Fengjuan Liu
- Xiao Wu
View Affiliations

Affiliations: Department of Nosocomial Infection, Affiliated Qingdao Central Hospital of Qingdao University, Qingdao Cancer Hospital, Qingdao, Shandong 266042, P.R. China, Department of Emergency Medicine, Affiliated Qingdao Central Hospital of Qingdao University, Qingdao Cancer Hospital, Qingdao, Shandong 266042, P.R. China, Department of Radiophysics, Affiliated Qingdao Central Hospital of Qingdao University, Qingdao Cancer Hospital, Qingdao, Shandong 266042, P.R. China, Ward for Phase I Clinical Trial, Affiliated Qingdao Central Hospital of Qingdao University, Qingdao Cancer Hospital, Qingdao, Shandong 266042, P.R. China, Department of Pulmonary and Critical Care Medicine, Affiliated Qingdao Central Hospital of Qingdao University, Qingdao Cancer Hospital, Qingdao, Shandong 266042, P.R. China
Published online on: January 22, 2024 https://doi.org/10.3892/etm.2024.12397
Article Number: 109
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is a harmful type of malignancy and the leading cause of cancer‑associated mortality. It is therefore imperative to develop novel drugs effective for treating this cancer. The Traditional Chinese Medicine compound Britannin has been previously reported to inhibit the development of certain cancers, such as pancreatic, breast and liver cancer. Moreover, Kruppel‑like factor 5 (KLF5) has been identified an on oncogene in lung cancer. In the present study, the possible regulatory effects and underlying mechanism of Britannin in lung cancer were investigated. A549 and 16HBE cells were treated with different concentrations of Britannin. Subsequently, Cell counting kit‑8, EdU staining and colony formation assays were used to detect the proliferative ability of these cells. Cell migration was detected by wound healing and Transwell assays, respectively. XF96 extracellular flux analyzer was used to analyze the extent of extracellular acidification and oxygen consumption rate in cells, whereas assay kits were used to detect glucose and lactic acid levels in the cell supernatant. The targeting effect between Britannin and the KLF5 protein was investigated using molecular docking technology. The protein expression levels of KLF5 in cells challenged with Britannin was detected by western blotting. Finally, overexpression of KLF5 in A549 cells was performed before cell proliferation, migration and the glycolysis rate were measured to explore the regulatory effects of Britannin. Britannin was found to inhibit the proliferation, migration and glycolysis of lung cancer cells, during which the protein expression levels of KLF5 were decreased. This suggests that Britannin regulated the expression of KLF5 in A549 cells. Overexpression of KLF5 reversed the inhibitory effects of Britannin on the proliferation, migration and glycolysis in lung cancer cells. In conclusion, these results suggest that Britannin can inhibit cell proliferation, migration and glycolysis by downregulating KLF5 expression in lung cancer cells.

View Figures

View References

1	Greenberg AK, Yee H and Rom WN: Preneoplastic lesions of the lung. Respir Res. 3(20)2002.PubMed/NCBI View Article : Google Scholar
2	Mao Y, Yang D, He J and Krasna MJ: Epidemiology of Lung Cancer. Surg Oncol Clin N Am. 25:439–445. 2016.PubMed/NCBI View Article : Google Scholar
3	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 71:209–249. 2021.PubMed/NCBI View Article : Google Scholar
4	Lemjabbar-Alaoui H, Hassan OU, Yang YW and Buchanan P: Lung cancer: Biology and treatment options. Biochim Biophys Acta. 1856:189–210. 2015.PubMed/NCBI View Article : Google Scholar
5	Bilfinger T, Keresztes R, Albano D and Nemesure B: Five-Year Survival Among Stage IIIA Lung Cancer Patients Receiving Two Different Treatment Modalities. Med Sci Monit. 22:2589–2594. 2016.PubMed/NCBI View Article : Google Scholar
6	Johnson ML and Patel JD: Chemotherapy and targeted therapeutics as maintenance of response in advanced non-small cell lung cancer. Semin Oncol. 41:93–100. 2014.PubMed/NCBI View Article : Google Scholar
7	Hui H, Wang M, Guo H, Wang Y and Shi B: Poziotinib-induced cutaneous adverse reactions in the treatment of non-small cell lung cancer: A case report. Int J Dermatol. 61:769–770. 2022.PubMed/NCBI View Article : Google Scholar
8	Leonardi GC, Oxnard GR, Haas A, Lang JP, Williams JS and Awad MM: Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer. J Immunother. 40:249–251. 2017.PubMed/NCBI View Article : Google Scholar
9	Ganapathy-Kanniappan S and Geschwind JF: Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer. 12(152)2013.PubMed/NCBI View Article : Google Scholar
10	Zhang L, Zhang Z and Yu Z: Identification of a novel glycolysis-related gene signature for predicting metastasis and survival in patients with lung adenocarcinoma. J Transl Med. 17(423)2019.PubMed/NCBI View Article : Google Scholar
11	Smolle E, Leko P, Stacher-Priehse E, Brcic L, El-Heliebi A, Hofmann L, Quehenberger F, Hrzenjak A, Popper HH, Olschewski H and Leithner K: Distribution and prognostic significance of gluconeogenesis and glycolysis in lung cancer. Mol Oncol. 14:2853–2867. 2020.PubMed/NCBI View Article : Google Scholar
12	Li X, Yang G, Li X, Zhang Y, Yang J, Chang J, Sun X, Zhou X, Guo Y, Xu Y, Liu J and Bensoussan A: Traditional Chinese medicine in cancer care: a review of controlled clinical studies published in chinese. PLoS One. 8(e60338)2013.PubMed/NCBI View Article : Google Scholar
13	Su XL, Wang JW, Che H, Wang CF, Jiang H, Lei X, Zhao W, Kuang HX and Wang QH: Clinical application and mechanism of traditional Chinese medicine in treatment of lung cancer. Chin Med J (Engl). 133(24):2987–2997. 2020.PubMed/NCBI View Article : Google Scholar
14	Wei Z, Chen J, Zuo F, Guo J, Sun X, Liu D and Liu C: Traditional Chinese Medicine has great potential as candidate drugs for lung cancer: A review. J Ethnopharmacol. 300(115748)2023.PubMed/NCBI View Article : Google Scholar
15	Mohammadlou H, Hamzeloo-Moghadam M, Yami A, Feizi F, Moeinifard M and Gharehbaghian A: Britannin a Sesquiterpene Lactone from Inula aucheriana Exerted an Anti-leukemic Effect in Acute Lymphoblastic Leukemia (ALL) Cells and Enhanced the Sensitivity of the Cells to Vincristine. Nutr Cancer. 74:965–977. 2022.PubMed/NCBI View Article : Google Scholar
16	Lu H, Wu Z, Wang Y, Zhao D, Zhang B and Hong M: Study on inhibition of Britannin on triple-negative breast carcinoma through degrading ZEB1 proteins. Phytomedicine. 104(154291)2022.PubMed/NCBI View Article : Google Scholar
17	Luo Y and Chen C: The roles and regulation of the KLF5 transcription factor in cancers. Cancer Sci. 112:2097–2117. 2021.PubMed/NCBI View Article : Google Scholar
18	Zhang H, Shao F, Guo W, Gao Y and He J: Knockdown of KLF5 promotes cisplatin-induced cell apoptosis via regulating DNA damage checkpoint proteins in non-small cell lung cancer. Thorac Cancer. 10:1069–1077. 2019.PubMed/NCBI View Article : Google Scholar
19	Tung CH, Huang MF, Liang CH, Wu YY, Wu JE, Hsu CL, Chen YL and Hong TM: alpha-Catulin promotes cancer stemness by antagonizing WWP1-mediated KLF5 degradation in lung cancer. Theranostics. 12:1173–1186. 2022.PubMed/NCBI View Article : Google Scholar
20	Lu X, Zhao N, Duan G, Deng Z and Lu Y: Testis developmental related gene 1 promotes non-small-cell lung cancer through the microRNA-214-5p/Kruppel-like factor 5 axis. Bioengineered. 13:603–616. 2022.PubMed/NCBI View Article : Google Scholar
21	Shi J, Yang C, An J, Hao D, Liu C, Liu J, Sun J and Jiang J: KLF5-induced BBOX1-AS1 contributes to cell malignant phenotypes in non-small cell lung cancer via sponging miR-27a-5p to up-regulate MELK and activate FAK signaling pathway. J Exp Clin Cancer Res. 40(148)2021.PubMed/NCBI View Article : Google Scholar
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
23	Zhang YF, Zhang ZH, Li MY, Wang JY, Xing Y, Ri M, Jin CH, Xu GH, Piao LX, Zuo HX, Jin HL, Ma J and Jin X: Britannin stabilizes T cell activity and inhibits proliferation and angiogenesis by targeting PD-L1 via abrogation of the crosstalk between Myc and HIF-1alpha in cancer. Phytomedicine. 81(153425)2021.PubMed/NCBI View Article : Google Scholar
24	Li K, Zhou Y, Chen Y, Zhou L and Liang J: A novel natural product, britanin, inhibits tumor growth of pancreatic cancer by suppressing nuclear factor-kappaB activation. Cancer Chemother Pharmacol. 85:699–709. 2020.PubMed/NCBI View Article : Google Scholar
25	Cui YQ, Liu YJ and Zhang F: The suppressive effects of Britannin (Bri) on human liver cancer through inducing apoptosis and autophagy via AMPK activation regulated by ROS. Biochem Biophys Res Commun. 497:916–923. 2018.PubMed/NCBI View Article : Google Scholar
26	Karlstaedt A, Barrett M, Hu R, Gammons ST and Ky B: Cardio-Oncology: Understanding the Intersections Between Cardiac Metabolism and Cancer Biology. JACC Basic Transl Sci. 6:705–718. 2021.PubMed/NCBI View Article : Google Scholar
27	Danhier P, Banski P, Payen VL, Grasso D, Ippolito L, Sonveaux P and Porporato PE: Cancer metabolism in space and time: Beyond the Warburg effect. Biochim Biophys Acta Bioenerg. 1858:556–572. 2017.PubMed/NCBI View Article : Google Scholar
28	Hong H, Luo B, Xie Z, Li M, Xu Q, He Z and Peng Z: Retracted: Britannin mediates apoptosis and glycolysis of T-cell lymphoblastic lymphoma cells by AMPK-dependent autophagy. J Biochem Mol Toxicol. e23211:2022.PubMed/NCBI View Article : Google Scholar
29	Gong T, Cui L, Wang H, Wang H and Han N: Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway. J Transl Med. 16(164)2018.PubMed/NCBI View Article : Google Scholar
30	Xia W, Bai H, Deng Y and Yang Y: PLA2G16 is a mutant p53/KLF5 transcriptional target and promotes glycolysis of pancreatic cancer. J Cell Mol Med. 24:12642–12655. 2020.PubMed/NCBI View Article : Google Scholar